LAWRENCEVILLE, N.J., March 24, 2022 (GLOBE NEWSWIRE) — Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company…
-Primary endpoint analysis expected early Q2 2022- -Final data expected Q2 2022- SAN DIEGO, March…
JERSEY CITY, N.J., March 24, 2022 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology…
CARLSBAD, Calif., March 24, 2022 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI), a clinical…
Founder and CEO, Hing C. Wong, Ph.D., to be guest at “Fireside Chat” MIRAMAR, Fla.,…
NEW ORLEANS and LONDON, March 24, 2022 (GLOBE NEWSWIRE) — Revolo Biotherapeutics (“Revolo Bio” or…
Validive® Phase 2b/3 VOICE Trial Continues Adding Sites in the U.S. and Europe Camsirubicin Phase…
New interim data from TACTI-002 (Part B) evaluating the combination of efti and pembrolizumab in…
SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) — VistaGen Therapeutics, Inc. (Nasdaq: VTGN)…
Longeveron management presents live at the Second Euro-Geroscience Conference and at a pre-meeting task force…
Trudhesa™ Exceeds Fourth Quarter 2021 Prescription Guidance; Strong Launch Continues Into 2022 Demonstrated by 157%…
SUNNYVALE, Calif., March 24, 2022 (GLOBE NEWSWIRE) — BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular…
On Track to Initiate Phase 1 Clinical Trials in Healthy Volunteers for SZN-1326 and SZN-043…
Building Momentum with Completion of Patient Enrollment in 4 Late-Stage Trials Multiple Late-Stage Clinical Trial…
Phase 3 DISRUPT study enrollment continues on course towards conducting interim futility analysis as anticipated…
CUPERTINO, Calif., March 24, 2022 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), (“Reviva” or…
NEW YORK, March 24, 2022 (GLOBE NEWSWIRE) — Dante Labs, a global leader in genomics…
SAN DIEGO, March 24, 2022 (GLOBE NEWSWIRE) — Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical…
Clinical trial programs advance to further assess psychedelic-assisted psychotherapy utilizing lead drug candidate MYCO-001 DENVER,…
Company received corrected FDA advice letter for Phase III trial with vilobelimab in hidradenitis suppurativa…